IgA Nephropathy Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about IgA Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Study of BHV-1400 in IgA Nephropathy

IgA Nephropathy
Biohaven Therapeutics Ltd.20 enrolled12 locationsNCT07054684
Recruiting
Phase 3

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 4

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

IgA Nephropathy
Calliditas Therapeutics AB60 enrolled38 locationsNCT06712407
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

IgA Nephropathy (IgAN)Early Initial Therapy
Sichuan Provincial People's Hospital200 enrolled1 locationNCT06676007
Recruiting
Phase 4

Nefecon and Ambrisentan in IgA Nephropathy

Chronic Kidney DiseaseIgA NephropathyProteinuria
The First Hospital of Jilin University129 enrolled1 locationNCT07030894
Recruiting
Phase 4

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India585 enrolled12 locationsNCT06676384
Recruiting

TESTING -ON Post-Trial ObservatioNal Cohort Study

Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852